dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· March 28, 2026

Analysts Constructive on The Procter & Gamble (PG) Amid Sluggish Consumer Sentiment

View original at finance.yahoo.com
Analysts Constructive on The Procter & Gamble (PG) Amid Sluggish Consumer Sentiment The Procter & Gamble Company (NYSE:PG) is included in our list of the best stocks to buy for financial stability.Analysts Constructive on The Procter & Gamble (PG) Amid Sluggish Consumer Sentiment Copyright: jetcityimage / 123RF Stock P…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • EPS growth guidance of 1% to 6% year-over-year

    60% confidence

  • Procter & Gamble has below-par growth compared with peers and limited upside for the stock

    60% confidence

  • Holds similar expectations for the company's earnings growth as for sales growth

    60% confidence

  • Expects Procter & Gamble's sales growth to be at the lower end of its target range amid higher energy prices and sluggish consumer sentiment

    60% confidence

  • Sales growth guidance of 1% to 5% year-over-year

    60% confidence

  • Certain AI stocks offer greater upside potential and carry less downside risk than Procter & Gamble

    60% confidence

  • Pampers AMORE is its most premium and absorbent diaper

    60% confidence

Data points we hold from this source

Procter & Gamble · analyst sentiment mixed43 percent
Procter & Gamble · analyst sentiment bullish54 percent
Procter & Gamble · implied upside20 percent
Procter & Gamble · consensus price target171 USD
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Analysts Constructive on The Procter & Gamble (PG) Amid Sluggish Consumer Sentiment: Source | Via News | fr.via.news